A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

NCT ID: NCT04487301

Last Updated: 2021-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-16

Study Completion Date

2021-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A cross-sectional, non-interventional study to assess walking performance, vascular function, and lower limb calcification in subjects with peripheral artery disease and end-stage kidney disease (PAD-ESKD) receiving hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease End Stage Renal Disease on Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥55 years of age or ≥45 years of age with diabetes
* Receiving maintenance HD in a clinical setting for at least 2 weeks prior to screening
* Resting ABI \<0.90 in either leg OR Resting TBI \<0.70 in either leg
* Symptomatic as characterized by a limitation in exercise performance

Exclusion Criteria

* Above-ankle amputation
* Chronic limb-threatening ischemia (Rutherford 4-6)
* Non-ambulatory status
* A condition other than PAD that limits ability to walk
* Open or endovascular revascularization within 3 months prior to baseline.
* Illnesses, conditions, or planned surgeries within the study period that will interfere with the interpretation of the study results
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanifit Therapeutics S. A.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alex Gold, MD

Role: STUDY_DIRECTOR

Sanifit Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Valley Renal Medical Group

Northridge, California, United States

Site Status

Horizon Medical Research

Coral Gables, Florida, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

St Louis Kidney Care

St Louis, Missouri, United States

Site Status

Mountain Kidney & Hypertension Associates

Asheville, North Carolina, United States

Site Status

Houston Medical Research

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNFCT2020-07

Identifier Type: -

Identifier Source: org_study_id